A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

被引：4
|
作者：
DiNardo, Courtney D. [1 ]
Olin, Rebecca [2 ]
Ishizawa, Jo [1 ]
Sumi, Hiroyuki [3 ]
Xie, Jingdong [4 ]
Kato, Kazunobu [4 ]
Kumar, Prasanna [4 ]
Andreeff, Michael [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif San Francisco, Hellen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[3] Daiichi Sankyo Co Ltd, Tokyo, Japan
[4] Daiichi Sankyo Inc, Basking Ridge, NJ USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-122241
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3932
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Itzykson, Raphael
    Thepot, Sylvain
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    [J]. BLOOD, 2010, 116 (21) : 199 - 199
  • [22] Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)
    Kadia, Tapan M.
    Benton, Christopher
    Erba, Harry P.
    Gandhi, Mitul
    Levy, Moshe Y.
    Percival, Mary-Elizabeth M.
    Ulrickson, Matthew
    Yimer, Habte
    Yu, Min
    Chen, Zi
    Wang, Jing
    Li, Mingyu
    Ahmad, Mohammad
    Yang, Dajun
    Zhai, Yifan
    [J]. BLOOD, 2022, 140 : 11659 - 11660
  • [23] Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
    Raffoux, Emmanuel
    Cras, Audrey
    Recher, Christian
    Boelle, Pierre-Yves
    de Labarthe, Adrienne
    Turlure, Pascal
    Marolleau, Jean-Pierre
    Reman, Oumedaly
    Gardin, Claude
    Victor, Maud
    Maury, Sebastien
    Rousselot, Philippe
    Malfuson, Jean-Valere
    Maarek, Odile
    Daniel, Marie-Therese
    Fenaux, Pierre
    Degos, Laurent
    Chomienne, Christine
    Chevret, Sylvie
    Dombret, Herve
    [J]. ONCOTARGET, 2010, 1 (01) : 34 - 42
  • [24] A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
    Oran, Betul
    de Lima, Marcos
    Garcia-Manero, Guillermo
    Thall, Peter F.
    Lin, Ruitao
    Popat, Uday
    Alousi, Amin M.
    Hosing, Chitra
    Giralt, Sergio
    Rondon, Gabriela
    Woodworth, Glenda
    Champlin, Richard E.
    [J]. BLOOD ADVANCES, 2020, 4 (21) : 5580 - 5588
  • [25] Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Sallman, David A.
    DeZern, Amy
    Sweet, Kendra
    Steensma, David P.
    Cluzeau, Thomas
    Sekeres, Mikkael
    Garcia-Manero, Guillermo
    Roboz, Gail
    McLemore, Amy
    McGraw, Kathy
    Puskas, John
    Zhang, Ling
    Bhagat, Chirag
    Graber, Armin
    Al Ali, Najla H.
    Padron, Eric
    Tell, Roger
    Lancet, Jeffrey E.
    Fenaux, Pierre
    List, Alan F.
    Komrokji, Rami S.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [26] Azacitidine plus gemtuzumab ozogamicin (GO): A novel combination in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly.
    Nand, Socha
    Godwin, John
    Smith, Scott
    Barton, Kevin
    Germano, Eliza
    Stiff, Patrick
    [J]. BLOOD, 2006, 108 (11) : 561A - 561A
  • [27] Tipifarnib in combination with idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
    Ravandi-Kashani, F.
    Kantarjian, H.
    Garcia-Manero, G.
    O'Brien, S.
    Verstovsek, S.
    Estrov, Z.
    Faderl, S.
    Giles, F.
    Wright, J.
    Cortes, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 351S - 351S
  • [28] Escalating doses of clofarabine (CLO) for high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia post-MDS (sAML) failing azacitidine (AZA)
    Braun, T.
    Raffoux, E.
    Prebet, T.
    Stamatoullas, A.
    Brechignac, S.
    Dreyfus, F.
    Samey, B.
    Ades, L.
    Vey, N.
    Dombret, H.
    Fenaux, P.
    Gardin, C.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S149 - S149
  • [29] Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies
    DiNardo, Courtney D.
    Olin, Rebecca
    Wang, Eunice S.
    Skikne, Barry
    Rosenthal, Joseph
    Kumar, Prasanna
    Sumi, Hiroyuki
    Hizukuri, Yoshiyuki
    Hong, Ying
    Patel, Parul
    Seki, Takahiko
    Duan, Tao
    Lesegretain, Arnaud
    Andreeff, Michael
    [J]. CANCER MEDICINE, 2024, 13 (14):
  • [30] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Wei, Yue
    Wierda, William G.
    Bueso-Ramos, Carlos E.
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2014, 124 (21)
12345